WHWK
Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.01
+4.15%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.89
From 52W high−40.98%
Volume520160.00
Market cap$171.60M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.89
From 52W high
−40.98%
Volume
520160.00
Market cap
$171.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
28.9
MomentumView details →
1D Return
+4.15%
YTD Return
+24.79%
SummaryUpdated Jun 1, 2026
Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company that underwent a significant strategic transformation in 2024. Originally founded as Aadi Biosciences and going public in 2017, the company initially focused on developing precision therapies for genetically-defined cancers, particularly through its drug FYARRO for rare sarcomas. In late 2024, the company rebranded to Whitehawk Therapeutics and pivoted its strategy to focus on developing advanced antibody-drug conjugates (ADCs) for cancer treatment, while divesting its original FYARRO asset to Kaken Pharmaceuticals.
Similar companies
Latest newsMore news →
Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 in Seoul supporting PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC, reinforcing the rationale for its next-generation PTK7-directed ADC HWK-007 in Phase 1 development.36d agoWhitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.39d ago